Differential medication overuse risk of novel anti-migraine therapeutics is a research paper published in Brain (2020). On theSindex it has a DataRank of 0. It has been cited 72 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Medical Research Council
Grant: MR/P006264/1
Wellcome Trust
Grant: 104033
EUROHEADPAIN
Grant: 602633
NIH
Grant: DA40688
Wellcome Trust
Grant: 104033/Z/14/Z
NIDA NIH HHS
Grant: R01 DA040688
DPST
Migraine Trust
Development and Promotion of Science and Technology Talents Project
Royal Thai Government
FWCI
5.10
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: a systematic literature review
Additional file 1 of The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: a systematic literature review
Additional file 1 of CGRP-targeted medication in chronic migraine - systematic review
Additional file 1 of CGRP-targeted medication in chronic migraine - systematic review
Additional file 1 of Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial
Additional file 1 of Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial
Additional file 2 of Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial
Additional file 2 of Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial
Additional file 3 of Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial
Additional file 3 of Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial
Additional file 4 of Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial
Additional file 4 of Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial